Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 in advanced non-small-cell lung cancer after multiple prior chemotherapies
2010-020116-11Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Luminespib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Tumor response and clinical benefit at 18 weeks. Started Jul 2010; status: terminated.
02
Drugs
Luminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-020116-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020116-11.